This comes at a challenging time for gene therapies, as multiple serious AEs and fatalities have been recently reported.

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Meanwhile, Merus, a Netherlands-based cancer cure developer, saw its shares jump after unveiling interim phase 2 data for its experimental antibody petosemtamab in combination with pembrolizumab for ...

Despite the long holiday weekend, news in biopharma never slows down. | This week on "The Top Line," we break down ...

The innovation addresses two of the construction industry’s most significant issues—cement’s carbon footprint and industrial ...